Drug Search Results
More Filters [+]

Procarbazine

Alternative Names: procarbazine, natulan, matulane
Latest Update: 2024-12-04
Latest Update Note: Clinical Trial Update

Product Description

Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Procarbazine)

Mechanisms of Action: Protein Synthesis Inhibitor,DNA Synthesis Inhibitor,RNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Canada | Chile | France | Germany | Greece | Hong Kong | India | Ireland | Italy | Japan | Lithuania | Malta | New Zealand | Pakistan | Peru | Portugal | Romania | Russia | Slovenia | Spain | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Radiation Therapy Oncology Group
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Procarbazine

Countries in Clinic: Spain

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Hodgkin Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BrEPEM-LH-22017

P2

Active, not recruiting

Hodgkin Lymphoma

2023-10-30

Recent News Events